IRTC: Medtech Reset And EPS Revisions Will Set Up Future Upside

Analysts have trimmed the iRhythm Holdings fair value estimate from $195.00 to about $178.93, reflecting a series of reduced Street price targets as models are updated for lower projected EPS and a reset in medtech valuations.

Analyst Commentary

Recent Street research on iRhythm Holdings shows a mix of optimism on the companys long term potential and caution around execution risks and sector level valuation resets. Price targets have been adjusted both up and down as models are refreshed for earnings forecasts and broader medtech sentiment.

Bullish Takeaways

Bullish analysts continue to carry Buy ratings even as they revise targets, signaling confidence that the current valuation still leaves room for long term execution on the business model.
Some research updates describe medtech fundamentals as healthy, which supports the view that iRhythm can participate in sector level growth once current volatility settles.
The adjustment of the 2026 adjusted EPS estimate to US$0.24 in one model, while lower than a prior US$0.35 figure, still implies expectations for profitability that underpin higher value than strictly near term revenue multiples might suggest.
Earlier target revisions to US$214 from US$242 indicate that even after cuts, some bullish analysts see the company belonging toward the higher end of the medtech peer group on valuation because of its positioning in cardiac monitoring.

Bearish Takeaways

Bearish analysts have trimmed price targets, with several reductions of US$30 to US$59 and others citing US$40 decreases, which points to reduced confidence in prior growth and margin assumptions used in earlier models.
Revisions tied to lower projected EPS, including the US$0.11 gap between the previous and updated 2026 adjusted EPS figure, highlight concern that earnings ramp up may be slower or more costly than previously modeled, which weighs on valuation.
Some research cites a reset in medtech valuations in a year with few product cycles, ACA and utilization worries, inflation pressures after the war, and capital flowing to data centers instead of healthcare, all of which make it harder to justify earlier, higher multiples for iRhythm.
Target cuts from firms such as JPMorgan and others that are described as lowering price objectives by US$40 or more suggest that a portion of the Street is focused on execution risk and sector wide derating rather than assuming a quick rebound in sentiment.

What's in the News

Recent coverage highlights iRhythm reporting its sixth consecutive quarter of over 20% revenue growth, supported by its core Zio Monitor business, expanding market share in wearable cardiac monitoring, AI driven efficiency gains, and positive free cash flow margin. The company also plans to launch an AI powered Zio MCT product in the first half of 2027. (Sources: recent news, first published May 18, 2026)
Analysts have focused on iRhythm's reported 23.9% annual revenue increase over the past two years and 27.5% earnings per share growth over five years, alongside gross margin expansion and SG&A leverage tied to automation and AI tools. (Sources: recent news, first published May 18, 2026)
Another set of reports points to iRhythm as a growth focused digital healthcare company in ambulatory cardiac monitoring, citing 23.3% annualized revenue growth over the past five years, healthy free cash flow margins, and heavy investment in research and development and collaborations to broaden its monitoring technology. (Sources: recent news, first published May 25, 2026)
Company guidance for full year 2026 revenue has been set at US$875 million to US$885 million. (Source: Company guidance, event dated May 2, 2026)
iRhythm has been active on the clinical evidence front, presenting multiple large scale real world studies at major cardiology meetings, including data on extended 14 day Zio monitoring in post ablation, pregnancy, diabetes, chronic kidney disease, and obesity populations. The company has also launched iRhythm Academy and a collaboration with Lucem Health to apply predictive AI to arrhythmia risk. (Sources: Company event disclosures, March to April 2026)

Valuation Changes

Fair Value: trimmed from $195 to about $178.93, a reduction of roughly 8% in the updated model.
Discount Rate: adjusted from 8.21% to approximately 7.84%, a modest decline that slightly lowers the required return used in the valuation work.
Revenue Growth: updated from 16.32% to about 15.98%, a small reduction in the projected revenue growth rate.
Net Profit Margin: revised from 5.65% to around 7.96%, reflecting higher modeled profitability in the outer years of the forecast.
Future P/E: reduced from about 122.61x to roughly 80.28x, bringing the implied earnings multiple closer to the updated profit and growth assumptions.

2 views

Key Takeaways

Expanding adoption among primary care and international markets, aided by partnerships and tailored selling models, is fueling sustained volume increases and diversified revenue streams.
Investment in advanced product features and AI analytics enhances differentiation and efficiency, supporting recurring usage, improved margins, and scalable long-term profitability.
Mounting competition, regulatory hurdles, reliance on key partners, and fragile profitability pose risks to growth, margins, and differentiation in a rapidly evolving market.

Catalysts

About iRhythm Technologies

A digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States.What are the underlying business or industry changes driving this perspective?

Increasing adoption of early arrhythmia detection by primary care physicians, enabled by EHR integrations and targeted partnerships, is expanding iRhythm's addressable market beyond traditional cardiology channels-this is leading to robust new account openings and sustained volume growth, likely to accelerate top-line revenue.
The growing push towards population health management, preventative care, and value-based reimbursement is aligning directly with Zio's evidence-supported, scalable monitoring platform, supporting both recurring usage and improved payer coverage, which should drive higher revenues and improved net margins over time.
Expansion into international markets (UK, EU, Japan), where iRhythm is seeing strong early uptake and building clinical validation, diversifies revenue streams and positions the company for long-term topline growth as aging populations drive global demand for remote cardiac monitoring.
Investment in the Zio ecosystem-including next-generation patches, enhanced form factors, and AI-powered analytics (such as the Lucem Health partnership)-is improving product differentiation, diagnostic yield, and workflow efficiency, likely leading to higher gross margins and operating leverage as software and data become a larger component of the business.
Strategic partnerships with innovative national accounts and health systems, as well as a "one-to-many" selling model, are reducing customer acquisition costs and setting up repeat monitoring opportunities, enhancing both recurring revenue and the sustainability of earnings growth.

iRhythm Technologies Earnings and Revenue Growth

iRhythm Technologies Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming iRhythm Holdings's revenue will grow by 16.0% annually over the next 3 years.
Analysts assume that profit margins will increase from -3.5% today to 8.0% in 3 years time.
Analysts expect earnings to reach $97.8 million (and earnings per share of $2.72) by about June 2029, up from -$27.8 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $113.2 million in earnings, and the most bearish expecting $82.4 million.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 80.7x on those 2029 earnings, up from -127.9x today. This future PE is greater than the current PE for the US Medical Equipment industry at 25.3x.
Analysts expect the number of shares outstanding to grow by 2.29% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.84%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Intensifying competition from established medtech and new wearable tech entrants, combined with the risk that new AI-driven, non-device-based monitoring may shrink iRhythm's addressable market, could force the company into higher R&D and marketing expenses, squeezing net margins and threatening long-term revenue growth.
Heavy reliance on a handful of channel and large IDN partners for expansion-particularly in innovative initiatives where prescribing patterns and account ramp-up are still unproven-creates execution and customer concentration risks that could lead to volatile or disappointing revenue if relationships falter or prescribing volumes underperform.
Regulatory risk remains significant, as ongoing FDA warning letter remediation, increased costs for compliance, and the need for a forthcoming third-party audit may drive up SG&A expenses; in addition, any delays or setbacks in obtaining FDA clearance for next-generation products (e.g., Zio MCT) could stall revenue growth and innovation.
Profitability is still fragile with ongoing adjusted net losses, dependence on non-GAAP metrics for margin improvement, front-loaded investments in infrastructure/innovation, and persistent free cash flow burn until at least 2026-raising the risk of value dilution or capital constraints if growth slows or targets are missed.
Industry pressure from potential reimbursement cuts, tightening data privacy/regulatory regimes internationally, and emerging commoditization in ambulatory cardiac monitoring could limit pricing power, compress gross margins, and reduce net revenue, particularly if iRhythm cannot maintain clear differentiation or quickly adapt to shifting payor and regulatory environments.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $178.93 for iRhythm Holdings based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $255.0, and the most bearish reporting a price target of just $147.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $1.2 billion, earnings will come to $97.8 million, and it would be trading on a PE ratio of 80.7x, assuming you use a discount rate of 7.8%.
Given the current share price of $108.11, the analyst price target of $178.93 is 39.6% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on iRhythm Holdings?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

IRTC: Future Performance Will Reflect Both Product Momentum And Regulatory Uncertainty